Screening for Prostatic Carcinoma: Case Finding is Not the Problem

Killian CS Chu TM . Prostate Specific Antigen: Questions often asked. Cancer Invest 1990; 8: 27–37.

Duffy MJ . PSA as a marker for prostate cancer: A critical review. Ann Clin Biochem 1996; 33: 511–9.

Woolf SH . Screening for prostatic cancer with prostate specific antigen. N Engl J Med 1995; 333: 1401–5.

Whitmore WF . Localized prostatic cancer: Management and detection issues. Lancet 1994; 343: 1263–7.

Schroder FH . Prostate cancer: To screen or not to screen. BMJ 1993; 306: 407–8.

Cooner WH Mosley BR Rutherford CL Beard JH Pond HS Bass B . Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 1988; 139: 758–61.

Cupp MR Oesterling JE . Prostate specific antigen, digital rectal examination and transrectal ultrasonography: Their roles in diagnosing early prostate cancer. Mayo Clin Proc 1993; 68: 297–306.

Cantalona WJ Smith DS Ratliff TL Dodds KM Coplen DE Yuan JJJ . Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61.

Cantalona WJ Richie JP Ahmann FR Hudson MA Scardino PT Flanigan RC . Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicentre clinical trial of 6630 men. J Urol 1994; 151: 1283–90.

Labrie F Candas B Cusan L Gomez J-L Diamond P Subura R . Diagnosis of advanced or non curable prostate cancer can be practically eliminated by prostate specific antigen. Urology 1996; 47: 212–7.

Leandri P Rossignol G Gautier JR Ramon J . Radical retropubic prostatectomy: Morbidity and quality of life. Experience with 620 consecutive cases. J Urol 1992; 147: 883–7.

Hanks GE Scardino PT . Does screening for prostate cancer make sense? Sci Am 1996; 275: 80–1.

Morton RA . Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994; 44: 637–45.

Van Dujinhoven HLP Pequeriaux NCV Van Zon JPHM Blankenstein MA . Large discrepancy between prostate specific antigen results from different assays during longitudinal follow up of a prostate cancer patient. Clin Chem 1996; 42: 637–41.

Dalkin BC Ahmann FR Kopp JB Cantalona WJ Ratliff TL Hudson MA . Derivation and application of upper limits for prostate specific antigen in men 50–74 years with no clinical evidence of prostate carcinoma. Br J Urol 1995; 76: 346–50.

Stormont TJ Zincke H Farrow GM Wilson TM Myers RP Oesterling JE . Clinical stage Bo or Tlc prostate cancer: Nonpalpable disease identified by elevated serum prostate specific antigen concentration. Urology 1993; 41: 3–8.

Labrie F Dupont A Suburu R Cusan L Tremblay M Gomez JL . Serum prostate specific antigen as a prescreening test for prostate cancer. J Urol 1992; 147: 846–52.

Gillat D Reynard JM . What is the “normal range” for prostate specific antigen? Use of a receiver operator characteristic curve to evaluate a serum marker. Br J Urol 1995; 75: 341–6.

Morgan TO Jacobsen SJ McCarthy WF Jacobsen DJ McCleod DG Moul JW . Age specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med 1996; 335: 304–10.

Oesterling JE . Age specific reference ranges for serum PSA. N Engl J Med 1996; 335: 345–6.

Tchetgen M-B Song JT Strawderman M Jacobsen SJ Oesterling JE . Ejaculation increases the serum prostate-specific antigen. Urology 1996; 47: 511–6.

Simak R Madersbaher Z-F Maier U . The impact of ejaculation on the serum prostate specific antigen. J Urol 1993; 150: 895–7.

Glenski WJ Klee GG Bergstralth EJ Oesterling JE . PSA: Establishment of the reference range for the clinically normal prostate gland and the effect of DRE, ejaculation and time on serum concentration. Prostate 1992; 21: 99–110.

Oesterling JE Jacobsen SJ Klee GG Pettersson K Piironen T Abrahamsson P . Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentration and ratios. J Urol 1995; 154: 1090–5.

Kleer E Oesterling JE . PSA and staging of localized prostate cancer. Urol Clin N Am 1993; 20: 695–704.

Labrie F Dupont A Cusan L Gomez JL Diamond P . Major advantage of early administration of endocrine combination therapy in advanced prostate cancer. Clin Invest Med (Canada) 1993; 16: 493–8